Category: 3. Business

  • Orbis International Appoints Kathleen Sherwin as President & CEO

    Orbis International Appoints Kathleen Sherwin as President & CEO

    Globally respected NGO leader joins Orbis to meet the growing global need for eye care

    NEW YORK, Jan. 12, 2026 /PRNewswire/ — Global eye care NGO Orbis International is pleased to welcome Kathleen Sherwin as President & CEO, effective immediately. Sherwin brings more than 25 years of experience advancing health equity, gender equality and sustainable development across the nonprofit and humanitarian sectors. Her career and values strongly align with Orbis’s vision of a world where everyone can access the eye care they need to thrive.

    “Kathleen’s passion for meaningful change and her unwavering commitment to equity and access strongly resonate with Orbis’s mission to eradicate curable blindness globally,” said John Slattery, Chair of the Board of Directors for Orbis International. “We are thrilled to welcome her as CEO and look forward to the impact she will help Orbis achieve for communities around the world.”

    Sherwin joins Orbis at a pivotal moment as the global health landscape evolves and the need for integrated, resilient health systems becomes increasingly urgent. She is focused on accelerating Orbis’s work to prevent blindness and restore sight while elevating eye health as a global health priority.

    “Eye health must be understood not as a standalone issue, but as a fundamental driver of equity, education, economic stability, and health system readiness,” Sherwin says. “Orbis has a critical role to play in ensuring eye care is fully integrated into broader health and development priorities.”

    [Sherwin’s high-resolution headshot is available for download here.]

    Before joining Orbis, Sherwin most recently served as Chief Strategy & Engagement Officer at Plan International, a global organization advancing children’s rights and equality for girls. In that role, she led strategy, partnerships, fundraising, communications, and policy, strengthening the organization’s global profile and long-term impact.

    Sherwin’s leadership has been consistently shaped by a commitment to advancing the health and rights of women and girls. She previously held senior roles at Women Deliver, including Interim President & CEO, and at Planned Parenthood Federation of America.

    Sherwin’s appointment marks an exciting new chapter for Orbis. Her strategic vision, global experience, and collaborative leadership will guide the organization as it continues working toward a future where everyone, everywhere, has access to quality eye care and the opportunity to reach their full potential.

    About Orbis International

    Orbis International works around the world to prevent blindness and restore sight for children and adults in places where eye care is out of reach—so vision problems don’t make it harder to learn, earn a living, or enjoy life. Around 1.1 billion people live with vision loss, but with the right care, 90% of it is completely avoidable. That is why Orbis trains doctors, nurses, and other eye care professionals to provide care in their own communities—and works to make sure people of all ages can access the eye exams, glasses, medicine, and surgeries they need to protect and restore their sight. Orbis began this work more than 40 years ago with the Flying Eye Hospital, a teaching hospital on a plane that brings expert training and care where they’re needed most. Today, we also work with local hospitals and clinics across Africa, Asia, and Latin America to make eye care available to more people, and we use and develop technology—like our award-winning Cybersight e-learning and telehealth platform, artificial intelligence screening, and virtual reality training—to help eye care teams treat patients more effectively. Orbis ranks in the top 3% of U.S. charities, having earned top marks for transparency and accountability from Charity Navigator, GuideStar, and the Better Business Bureau. To learn more, please visit orbis.org.

    Media Contact
    Jenna Montgomery
    Associate Director, Global Communications and Marketing
    Orbis International
    [email protected]

    SOURCE Orbis International

    Continue Reading

  • Trump faces extraordinary moment in spat with Fed chair Powell

    Trump faces extraordinary moment in spat with Fed chair Powell

    Faisal IslamEconomics editor

    Reuters Donald Trump appears next to Jerome Powell, who is carrying a white hard hat, during a visit to the Federal Reserve building as it undergoes renovations.Reuters

    It is extraordinary enough to see the world’s top central banker make an unscheduled video statement on social media. My first thought upon seeing the post from the Federal Reserve chair Jerome Powell was: “Is this an AI deepfake?”

    That sense did not go away as I listened to what were indeed the real words of the world’s most important financial official.

    The background here is a long-running spat between President Trump and the man responsible for setting interest rates in the US and indirectly much of the rest of the world.

    In theory, this has officially been about the cost of a renovation project at the Federal Reserve, the US equivalent of the Bank of England. The president even took his motorcade over to the Fed’s building to inspect the work.

    At the same time, President Trump has attempted to criticise, interfere and influence the highly independent setting of interest rates by Powell, through criticism and the appointment of his own favourite economists. The aim appears to be to try to massage down US interest rates.

    In the early hours of this morning, a softly spoken Powell revealed that the Department of Justice (DoJ) had served his institution with criminal indictments over his testimony on the building works. But he also said publicly what he had not before. The “unprecedented” DoJ moves “should be seen in the broader context of the administration’s threats and ongoing pressure”.

    Actions over the Fed building were “pretexts”, he said. “The threat of criminal charges is a consequence of the Federal Reserve setting interest rates based on our best assessment of what will serve the public, rather than following the preferences of the president.”

    There are unhappy international precedents for this in developing and emerging economies, where independent central bank governors can often be the first to see the wrath of elected governments attempting to shake off the restraints of expert institutions. Think Turkey and Zimbabwe.

    Powell said this morning: “This is about whether the Fed will be able to continue to set interest rates based on evidence and economic conditions, or whether instead, monetary policy will be directed by political pressure or intimidation.”

    This matters not just technically for American mortgage rates or US markets. Federal Reserve independence is the anchor for stability across global markets. This is not to say they always make the right decisions or are beyond criticism. But Powell is suggesting in clear terms that this is something much bigger than that.

    In a different context, during the infamous Liz Truss mini-budget, it was noises from Truss backers raising questions about the Bank of England that contributed to the chaos.

    In this context, it is worth watching the key market for US Treasuries, the safe haven asset of choice in times of instability. Will they respond to Powell’s public words, or the threat of criminal action?

    It might be argued that Powell’s term is up in May and he will be replaced, probably by a Trump-friendly economist, so does not make a difference. It does raise the stakes however. US interest rates are decided by a committee vote, not just the chair.

    There has been some wild talk that the US administration could choose to weaponise some of the Fed’s powerful global markets tools to coerce other countries in its tariff war, including allies. Bluntly, that use of what is known as swap lines, massive dollar funding at times of stress, would not have been possible under Powell. Is that where this is now going?

    More broadly it is difficult to detach the Powell intervention from what is going on elsewhere in the US. In recent days we have seen the deployment of militarised immigration police, routine threats the US could acquire sovereign territory from Nato allies, while the Supreme Court is about to confirm if his main economic policy has been illegal.

    There are some Republicans in Congress who will feel deeply uncomfortable about this Powell development in particular. The head of a central bank is someone with an alternative pole of power who, by design, must speak truth to power.

    Even Powell’s unscheduled appearance might cause a reaction in markets, as occurred when Andrew Bailey spoke to BBC cameras in Washington DC in the middle of the mini-budget crisis.

    It is worth noting that the most significant moment of pause in the Trump agenda occurred last April, when the chaotic approach to tariffs fell foul of the global bond markets before the stabilising influence of the Treasury Secretary Scott Bessent took control.

    The Powell moment could see a repeat.

    Continue Reading

  • What caused Instagram’s password change emails? Company dismisses data breach rumours

    What caused Instagram’s password change emails? Company dismisses data breach rumours

    What caused Instagram’s password change emails? Company dismisses data breach rumours

    The internet was in a constant state of frenzy over the past few days as Instagram users received suspicious password change emails; however, the Meta-owned photo and video-sharing platform has denied falling prey to any breaches.

    The purported, suspicious-looking password reset emails caused fears of a big-scale hack.

    Directly addressing the situation on Sunday, the company noted that the influx of emails was a technical glitch, not a cyberattack.

    Was Instagram users’ data really stolen?

    This official denial is in direct contradiction with earlier reports, as antivirus software company Malwarebytes on January 9 shared a concerning update on Bluesky, claiming that cybercriminals successfully stole sensitive information from 17.5 million Instagram accounts.

    As per the antivirus company, this compromised data includes usernames, physical addresses, phone numbers, and email addresses. The Bluesky post also warned that this data is available for sale on the dark web and is likely to be abused by cybercriminals.

    Why instagram sent password reset emails?

    Notwithstanding such grave allegations, Instagram, in a post on X, clarified that user data is safe, while admitting that they fixed an issue that allowed an external party to request password reset emails for some people.

    The Meta-owned platform did not provide specific details about this external party or the nature of the issue; instead, it simply advised users to disregard the notifications.


    Continue Reading

  • Oil dips as investors assess Iran supply, Venezuelan export resumption – Reuters

    1. Oil dips as investors assess Iran supply, Venezuelan export resumption  Reuters
    2. Natural Gas and Oil Forecast: WTI & Brent Rebound on Breakouts Despite 2026 Oversupply Fears  FXEmpire
    3. Crude Oil Prices Boosted by Dollar Weakness and Iranian Protests  TradingView — Track All Markets
    4. Brent price stock BRNT slips in London as Iran headlines cool and Venezuela barrels line up  TechStock²
    5. US, Iran, and Middle East Risks Lift WTI Near $60  FOREX.com

    Continue Reading

  • FTI Consulting Expands Transactions Communications

    FTI Consulting Expands Transactions Communications

    Washington, D.C., Jan. 12, 2026 — FTI Consulting, Inc. (NYSE: FCN) today announced the expansion of its transactions, shareholder activism and issues management capabilities with the appointments of Dan Scorpio and Heather Wilson as Senior Managing Directors within the firm’s Strategic Communications segment.

    “Guiding a transaction from announcement through close has never been more challenging with complex, intertwined stakeholder risks that pose meaningful threats to successful close and value realization,” said Pat Tucker, Americas Head of M&A and Activism for the Strategic Communications segment at FTI Consulting. “The dedicated, multi-disciplinary M&A team we’ve assembled is unique and enables our clients to understand, anticipate and mitigate risks to capture transaction value. The addition of Heather and Dan, and geographic expansion in the Midwest and West Coast, is an important milestone for our transaction and overall event-driven communications offering that will have an immediate impact for our clients.”

    Mr. Scorpio, who is based in Chicago, has more than a decade of experience leading high-profile M&A and reputational engagements for Fortune 500 companies, private equity and family businesses such as T-Mobile, Keurig Dr Pepper, IFF and Pritzker Private Capital, as well as Medline on its 2025 IPO, the largest globally since 2021. In his role, Mr. Scorpio will advise clients on M&A transactions, shareholder activism defense and financial communications issues.

    Prior to joining FTI Consulting, Mr. Scorpio was a Managing Director and Head of the M&A and Activism practice at H/Advisors Abernathy, where he provided strategic communications, stakeholder engagement and reputation management counsel to executive leadership teams and boards of directors. He has presented at the Garrett Institute and Corporate Counsel Institute and at industry forums hosted by National Investor Relations Institute, National Association of Corporate Directors and the Society for Corporate Governance.

    Commenting on his appointment, Mr. Scorpio said, “I am thrilled to join FTI Consulting and its rapidly growing M&A and Activism team. FTI Consulting’s differentiated offering is resonating in today’s dynamic marketplace, as clients are demanding experienced counsel, data-driven insights and highly tailored strategic execution through the moments that matter most. As the M&A market gains momentum in an increasingly complex global geopolitical environment, it’s clear to me that the integrated resources of FTI Consulting are best suited to solve companies’ most pressing challenges and partner with clients to achieve their business goals.”

    Ms. Wilson, who is based in Los Angeles, has deep expertise in transactions, crisis and issues management. She has worked across a range of industries, including for organizations such as IBM, HP, AbbVie, Mattel, the state of California and Goop, and for venture capital and private equity funds on issues including crisis response, high-profile litigation, transaction communications and investor relations, and public affairs. She is a frequent public speaker on crisis management and special situations.

    At FTI Consulting, Ms. Wilson will advise clients around transactions and crisis situations and bolster the firm’s presence on the West Coast. Prior to joining FTI Consulting, Ms. Wilson was the Senior Vice President and Chief Marketing and Communications Officer at AccentCare, a national provider of home health services, where she led all communications, crisis and issues management, digital and brand marketing. Earlier in her career, she was a journalist at CBS Marketwatch, Fox News and CNBC.

    Commenting on her appointment, Ms. Wilson said, “FTI Consulting has a world-class strategic communications team with deep and broad expertise to handle our clients’ unique needs through any crisis or deal lifecycle. I’m excited to join this integrated team and expand our footprint in the Golden State.”

    FTI Consulting’s integrated transaction communications offering supports clients in realizing deal success by delivering investor support and approval, mitigating political risk for regulatory clearance and setting clients up for integration success. The team taps into the firm’s global expertise across corporate reputation, investor relations, public affairs, people and transformation and digital strategy. This work is complemented by FTI Consulting’s broader M&A and Activism services, including merger integration, business transformation, media relations, proxy advisory, investor engagement, ESG strategy and strategic advisory work for chief financial officers.

    About FTI Consulting
    FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of September 30, 2025. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.70 billion in revenues during fiscal year 2024. More information can be found at www.fticonsulting.com.

    FTI Consulting, Inc. 
    555 12th Street NW
    Washington, DC 20004
    +1.202.312.9100

    Investor Contact: Mollie Hawkes
    +1.617.747.1791
    mollie.hawkes@fticonsulting.com

    Media Contact: Sam Ford
    +1.617.480.7402
    samantha.ford@fticonsulting.com

    Source: FTI Consulting, Inc.

    Continue Reading

  • Strategic Partnerships | Andreessen Horowitz

    Our portfolio companies are building technology that rearchitects how we build, work, and thrive together. But transformative technology only matters if it reaches the right people and institutions. Our strategic partners offer decades of domain expertise and operational muscle to help our founders deliver on their boldest ambitions and turn their innovations into real-world impact at scale.

    Continue Reading

  • AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

    AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

    –       RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancers

    NORTH CHICAGO, Ill. and YANTAI, China, Jan. 12, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody. RC148 is currently being developed by RemeGen as a monotherapy and in combination regimens across multiple advanced solid tumors.

    PD-1/VEGF-targeted bispecific antibodies represent a new class of cancer therapies that aim to help the immune system fight tumors more effectively and potentially overcome tumor resistance mechanisms by blocking both PD-1 and VEGF simultaneously. Additionally, given their potential to modulate both immune suppression and foster a favorable tumor microenvironment for antibody-drug conjugate (ADC) activity, PD-1/VEGF bispecific antibodies are also being explored in combination with ADCs. In early clinical studies, RC148 has shown initial favorable antitumor activity in combination with an ADC.

    RC148 further strengthens AbbVie’s diverse oncology portfolio. In particular, it may offer new opportunities to explore combination regimens with AbbVie’s ADCs such as investigational telisotuzumab adizutecan (Temab-A), across multiple solid tumors with high unmet need including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

    “Our partnership with RemeGen reflects AbbVie’s commitment to not only advance novel oncology treatments, but also to build strong collaborations with biopharmaceutical innovators globally as an increasingly important source of scientific and clinical progress,” said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology at AbbVie. “By combining the immune checkpoint inhibition and anti-angiogenic activity of RC148 together with the targeted cytotoxic activity of ADCs, we have the potential to identify meaningful options for patients across a range of solid tumors.”

    “This collaboration is a significant milestone for RemeGen, highlighting the innovative potential of RC148 in addressing critical unmet medical needs in cancer treatment,” said Dr. Jianmin Fang, chief executive officer of RemeGen. “The deal further underscores RemeGen’s commitment to bringing cutting-edge therapies to patients worldwide. Working with AbbVie, we look forward to maximizing RC148’s clinical and commercial potential in China and globally.”

    Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize RC148 outside of the Greater China territory. RemeGen will receive an upfront payment of USD $650 million and is eligible to receive up to USD $4.95 billion in aggregate development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales outside the Greater China territory.

    About AbbVie
    AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube. 

    About AbbVie in Oncology
    AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

    Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world’s most widespread and debilitating cancers. As we work to have a remarkable impact on people’s lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

    About RemeGen
    RemeGen Co., Ltd. is a leading innovative biopharmaceutical company in China focused on the discovery, development, manufacturing and commercialization of proprietary biologics. The company is dual-listed on the Hong Kong Stock Exchange and the STAR Market of the Shanghai Stock Exchange.

    RemeGen has built a highly differentiated pipeline across autoimmune, oncology and ophthalmology, with a proven ability to rapidly translate innovative science into clinically and commercially meaningful medicines. Its two flagship products, telitacicept and disitamab vedotin, have received approvals for a total of six indications in China, underscoring RemeGen’s strong capabilities in first-/best-in-class biologics discovery, efficient clinical execution and successful commercialization. Additional information is available on the company’s website at https://www.remegen.com/

    Forward-Looking Statements
    Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

     

    SOURCE AbbVie


    Continue Reading

  • UK set for a ‘booming’ mortgage market, say analysts

    UK set for a ‘booming’ mortgage market, say analysts

    Kevin PeacheyCost of living correspondent

    Getty Images Young couple look at houses for sale in an estate agent's windowGetty Images

    Competition among lenders suggests that mortgage rates could be cut in the coming weeks, according to brokers and analysts.

    In a newly-published report, financial information service Moneyfacts said “expectations are high for a booming market in 2026”.

    Its data shows the choice of mortgage products has risen to its highest level in 18 years, with first-time buyers now also being helped by looser requirements from lenders.

    Mortgage rates fell over the last year, but wider global and economic uncertainty still has the potential to derail any further improvements. Some borrowers also still face a financial hit when their current deal comes to an end.

    More than eight in 10 mortgage customers have fixed-rate deals.

    The interest rate on this kind of mortgage does not change until the deal expires, usually after two or five years, and a new one is chosen to replace it.

    In August last year, the average two-year fixed mortgage rate dipped below 5% for the first time since former Prime Minister Liz Truss’s mini-budget in September 2022.

    Rates have fallen further, with some movement in recent days, and Moneyfacts has predicted more declines early this year.

    “Expectations are high for a booming market in 2026. Mortgage rates are lower year-on-year, and the choice of deals is abundant,” said Moneyfacts.

    “First-time buyers are not being left behind by this progress.”

    Buying a property is a huge financial stretch for many first-time buyers, and the number of suitable homes on the market is limited.

    But rising wages also mean that mortgage costs as a share of income are at their lowest for a few years for first-time buyers.

    Regulators have recently allowed lenders to be more flexible with mortgage affordability so Jo Jingree, director of broker Mortgage Confidence, said more innovative products to help people buy a first home were now available.

    “These include allowing borrowing up to six times your income, where affordability allows,” she said.

    Some lenders were offering low, or no, deposit mortgages, she added. Family and friends were able to support borrowers through new, so-called joint borrower, sole proprietor mortgages.

    Local housing markets differ

    In general, mortgage brokers have suggested there is some pent-up demand among potential buyers who were waiting for the Budget and the festive period to be over before making firm plans to move.

    However, such a judgement is difficult to make with any certainty. Industry predictions made before Christmas suggested sales could fall over the year as a whole compared with 2025.

    Aaron Strutt, from broker Trinity Financial, said 1.8 million borrowers were coming to the end of their fixed rates and competition between the lenders to issue more mortgages was likely to be even stronger this year.

    “We can expect to see some more criteria easing and hopefully even cheaper fixed rates,” he said.

    Housing commentators have pointed to the relative stability of prices in recent times.

    Buying agent Henry Pryor said the UK housing market had moved on from the “red-hot” period for sellers in the aftermath of Covid.

    “There are distinct differences as always as you move to higher prices and from parish to parish but in general the UK housing market remains healthy and largely predictable,” he said.

    “Interest rates seem to be coming down, [housing] supply remains constrained but people have choice and are more cautious. The biggest problem remains price – sellers think that it’s 2022 while buyers think it’s 2014.”


    Continue Reading

  • Sukuk Market: Strong Growth To Continue – S&P Global

    1. Sukuk Market: Strong Growth To Continue  S&P Global
    2. Global sukuk market enters 2026 on solid footing after $300bn issuance: Fitch  Arab News PK
    3. Global sukuk outstanding surpasses $1 trillion in 2025, led by GCC and ASEAN regions  Economy Middle East
    4. Sukuk market strength carries into 2026  Mettis Global

    Continue Reading

  • The United States Welcomes Qatar’s Signing of Pax Silica Declaration

    The United States Welcomes Qatar’s Signing of Pax Silica Declaration

    Today, Qatar signed the Pax Silica Declaration, marking a historic milestone in the region’s economic integration.  Together, the United States of America and Qatar affirm a new geopolitical consensus that economic security is national security, and national security is economic security. Qatar’s leadership and commitment to investing in secure energy, advanced technology, and critical minerals supply chains make it an indispensable partner in this effort, placing Qatar in the vanguard of nations that will drive the next stage of global economic growth.

    Qatar’s accession to Pax Silica was signed by Under Secretary of State for Economic Affairs Jacob Helberg and Minister of State for Foreign Trade Affairs Ahmed bin Mohammed Al-Sayed. The United States and Qatar affirmed their commitment to pursue multilayered partnerships that strengthen supply chain security, address coercive dependencies and single points of failure, and advance the adoption of trusted technology ecosystems. They will explore opportunities to partner on flagship projects across global technology stacks, including connectivity and digital infrastructure, compute and semiconductors, advanced manufacturing, logistics, mineral refining and processing, and energy.

    Pax Silica is an economic security coalition built for the AI age.  This is the first time countries are organizing around compute, silicon, minerals, and energy as shared strategic assets.

    The United States welcomed Qatar as the eighth Pax Silica signatory. They joined signatories from Australia, Israel, Japan, Republic of Korea, Singapore, and the United Kingdom. Additional signatories are expected to follow.   

    Pax Silica is a positive-sum partnership of nations that want to remain competitive and prosperous.

    For media inquiries, please submit questions here, and stay updated by following @UnderSecE on X.

    For more information, visit Pax Silica.

    Read Under Secretary Helberg’s Remarks on the Accession of Qatar to the Pax Silica Declaration

    Continue Reading